Authors


Brian Henderson, PhD

Latest:

Is circulating heat shock protein 60 a marker for susceptibility to cardiovascular disease in patients with diabetes?

The vital cell stress protein, heat shock protein (Hsp)60, has recently been found in the circulation of healthy subjects over an extremely large concentration range. We performed an analysis of subjects with diabetes to determine whether Hsp60 is associated with biochemical markers of cardiovascular disease. Results showed that high circulating levels of Hsp60 are associated with clinically manifest cardiovascular disease. Hsp60 has cytokine-like actions, which may be responsible for this association.


Steven P. Levine, MD

Latest:

Integrated Care and Treatment-Resistant Depression

Closing thoughts regarding a discussion on improving the management of patients with treatment-resistant depression using newer treatment approaches in a more standardized fashion.


Vera Barton-Maxell, PhD, APRN, FNP-BC, CHFN

Latest:

Preempting Stage A Heart Failure In Primary Care

Barton-Maxell details the importance of caring for stage A heart failure patients in the primary care setting.



Edward R. Melnick, MD, MHS

Latest:

EHR Usability: Addressing the "(I Can't Get No) Satisfaction" Sentiment

Techniques to identify and address EHR usability challenges.




Maria G. Franzosi, MSc

Latest:

The prognostic role of metabolic syndrome after myocardial infarction

We evaluated the prognostic role of metabolic syndrome after myocardial infarction and found that metabolic syndrome correlated with an increased risk of cardiovascular events and death. The risk of developing diabetes decreased with weight loss in patients with metabolic syndrome. These results indicate that a more aggressive approach to the treatment of patients with metabolic syndrome, particularly with regard to changes in lifestyle, would be beneficial.


Douglas Dulli, MD, MS, is professor of neurology, University of Wisconsin Hospital

Latest:

Warfarin versus aspirin for stroke prevention in the elderly study: Putting fears to rest

The article by Mant and colleagues concerning the Birmingham Atrial Fibrillation Treatment of the Aged (BAFTA) study is a welcomed addition to the now vast literature regarding the relative benefits of warfarin anticoagulation in patients with atrial fibrillation.


M. Houman Fekrazad, MD

Latest:

Localized Chemotherapy Delivery: A Brief Review

The concept of treating malignancies using a regional approach originated in 1950, when Klopp and associates began to infuse nitrogen mustard into the arterial supply of various neoplasms.


Albert Yuh-Jer Shen, MD1

Latest:

Intracranial hemorrhage in atrial fibrillation: Is there a racial/ethnic difference?

We evaluated a multiethnic cohort of subjects with nonrheumatic atrial fibrillation hospitalized over a 6-year period to determine the racial and ethnic differences in the risk of intracranial hemorrhage (ICH) and the effect of warfarin treatment on ICH risk. Treatment with warfarin was associated with a 2-fold greater risk of ICH in whites, a 4- to 5-fold greater risk in both blacks and Hispanics, and a 15-fold greater risk in Asians. After adjusting for established stroke risk factors and warfarin use, Asians were 4 times as likely as whites to have ICH, whereas blacks and Hispanics were twice as likely.





Jeroen J. Bax, PhD1: From the 1Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands

Latest:

Prognostic value of multislice computed tomography coronary angiography

We evaluated 100 subjects who underwent multislice computed tomography (MSCT) to assess the presence and severity of coronary artery disease (CAD) and to determine the occurrence of coronary events (including cardiac death, nonfatal myocardial infarction, unstable angina requiring hospitalization, and revascularization) over a follow-up period of 16 months.


Vijayalakshmi Iyer, PhD & Erin Burns, PhD

Latest:

Smoking Cessation Counseling in Lung Cancer Screening Programs

Most programs offer smoking cessation counseling as part of the shared decision making visit and throughout the program. Some LCS programs also order pulmonary function studies for new patients to provide an overall picture of lung health.


John Crowley

Latest:

John Crowley on the 1-Year Anniversary of a Rare First Address

John Crowley, the President and CEO of Amicus Therapeutics, sat down with Rare Disease Report at the 14th Annual WORLDSymposium in San Diego to discuss the President's mention of rare diseases.


Northwestern University, Chicago, IL.

Latest:

Diabetes-related poor outcomes in chronic heart failure: Complex interactions with sex and age

This propensity-matched study, in which patients with and without diabetes were well balanced in all measured baseline characteristics, including traditional risk factors and comorbidities, found that diabetes was associated with increased mortality and hospitalization in ambulatory patients who had chronic, mild-to-moderate heart failure and were receiving angiotensin-converting enzyme inhibitors. These findings also highlight the sex- and age-related variations in the effect of diabetes in these patients.



the Department of Cardiology, Concord Hospital,

Latest:

Combining warfarin and antiplatelet therapy after coronary stenting

We conducted an observational study to compare singleantiplatelet therapy with dualantiplatelet therapy among patients requiring long-term warfarin therapy after coronary stenting. Results showed that there was no difference in mortality or myocardial infarction between the 2 treatment regimens at 6 months, with no excess in-hospital bleeding; however, larger trials are needed to determine firm recommendations.


Diane Blum, MSW

Latest:

Way Too Much Info

The Internet can be an amazingly useful educational resource for patients who have been diagnosed with cancer. It can also be the source of potentially dangerous misinformation.






Jivesh Sharma, MD

Latest:

Opportunities and Challenges: A Time to Reflect at the End of a Busy Year

It is the final month of what has been economically a very tough year. Oncology centers and practices continue to face declining reimbursements on all service lines, and most have had either flat or lower revenues.




Fred Eberlein

Latest:

TechSectors: Connectivity: Improving Physician-Patient Communication

More than ever before, healthcare professionals are strapped for time.


© 2024 MJH Life Sciences

All rights reserved.